EEG Frequency Correlates with α2-Receptor Density in Parkinson's Disease
- PMID: 38397446
- PMCID: PMC10886955
- DOI: 10.3390/biom14020209
EEG Frequency Correlates with α2-Receptor Density in Parkinson's Disease
Abstract
Introduction: Increased theta and delta power and decreased alpha and beta power, measured with quantitative electroencephalography (EEG), have been demonstrated to have utility for predicting the development of dementia in patients with Parkinson's disease (PD). Noradrenaline modulates cortical activity and optimizes cognitive processes. We claim that the loss of noradrenaline may explain cognitive impairment and the pathological slowing of EEG waves. Here, we test the relationship between the number of noradrenergic α2 adrenoceptors and changes in the spectral EEG ratio in patients with PD.
Methods: We included nineteen patients with PD and thirteen healthy control (HC) subjects in the study. We used positron emission tomography (PET) with [11C]yohimbine to quantify α2 adrenoceptor density. We used EEG power in the delta (δ, 1.5-3.9 Hz), theta (θ, 4-7.9 Hz), alpha (α, 8-12.9 Hz) and beta (β, 13-30 Hz) bands in regression analyses to test the relationships between α2 adrenoceptor density and EEG band power.
Results: PD patients had higher power in the theta and delta bands compared to the HC volunteers. Patients' theta band power was inversely correlated with α2 adrenoceptor density in the frontal cortex. In the HC subjects, age was correlated with, and occipital background rhythm frequency (BRF) was inversely correlated with, α2 adrenoceptor density in the frontal cortex, while occipital BRF was inversely correlated with α2 adrenoceptor density in the thalamus.
Conclusions: The findings support the claim that the loss or dysfunction of noradrenergic neurotransmission may relate to the parallel processes of cognitive decline and EEG slowing.
Keywords: EEG; Parkinson’s; dementia; locus coeruleus; noradrenaline; α2 adrenoceptor.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
Noradrenergic alterations in Parkinson's disease: a combined 11C-yohimbine PET/neuromelanin MRI study.Brain. 2024 Apr 4;147(4):1377-1388. doi: 10.1093/brain/awad338. Brain. 2024. PMID: 37787503 Free PMC article.
-
Evoked mid-frontal activity predicts cognitive dysfunction in Parkinson's disease.J Neurol Neurosurg Psychiatry. 2023 Nov;94(11):945-953. doi: 10.1136/jnnp-2022-330154. Epub 2023 Jun 1. J Neurol Neurosurg Psychiatry. 2023. PMID: 37263767 Free PMC article.
-
Brain oscillatory patterns in mild cognitive impairment due to Alzheimer's and Parkinson's disease: An exploratory high-density EEG study.Clin Neurophysiol. 2022 Jun;138:1-8. doi: 10.1016/j.clinph.2022.01.136. Epub 2022 Feb 14. Clin Neurophysiol. 2022. PMID: 35349920
-
Influence of Fragrances on Human Psychophysiological Activity: With Special Reference to Human Electroencephalographic Response.Sci Pharm. 2016 Nov 29;84(4):724-751. doi: 10.3390/scipharm84040724. Sci Pharm. 2016. PMID: 27916830 Free PMC article. Review.
-
Changes in theta activities in the left posterior temporal region, left occipital region and right frontal region related to mild cognitive impairment in Parkinson's disease patients.Int J Neurosci. 2017 Jan;127(1):66-72. doi: 10.3109/00207454.2016.1143823. Epub 2016 Feb 17. Int J Neurosci. 2017. PMID: 26785609
References
-
- Sommerauer M., Fedorova T.D., Hansen A.K., Knudsen K., Otto M., Jeppesen J., Frederiksen Y., Blicher J.U., Geday J., Nahimi A., et al. Evaluation of the noradrenergic system in Parkinson’s disease: An 11C-MeNER PET and neuromelanin MRI study. Brain. 2018;141:496–504. doi: 10.1093/brain/awx348. - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical